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Abstract 
Background :To evaluate the efficacy of monthly 
intravitreal bevacizumab injections (1.25 mg/.05 ml) 
in improving or stabilizing visual acuity measured 
by Snellen’s visual acuity charts for diabetic 
retinopathy. 
Methods: This was a  prospective Quasi 
experimental study of 59 diabetic patients having  
diabetic retinopathy with indication of intravitreal 
anti VEGF,Bevacizumab. Patients diagnosed of  
having fresh vitreous haemorrhage and diabetic 
macular edema were included. Maximum three 
intravitreal bevacizumab injections were given, each 
with a dose of 1.25mg in 0.05ml(at 0month, 1 month, 
2 months) with final follow up at the period of 3 
months. The criteria for improvement was a gain of 
at least one line on Snellen’s visual acuity chart, 
compared to the baseline while stabilization was 
considered if the visual acuity was unchanged 
relative to the baseline. 
Results: A total of 59 patients, 25 (49.1%) males and 
34 (50.84%) females , having age range 40-65 
years,were given intravitreal injection. Twenty six 
eyes (44.06%) with diabetic macular edema showed 
improvement while visual acuity was stabilized in 4 
eyes (6.7%). In patient with vitreous hemorrhage, 27 
eyes (45.76%) showed improvement while 
stabilization of visual acuity was noted in 2 eyes 
(3.3%). No patient with worsening of visual acuity 
was noted. 
Conclusion: Intravitreal Bevacizumab is very 
effective in improving the visual outcome in diabetic 
patients having macular edema and vitreous 
hemorrhage. 
Key Words: Visual Outcome, Intravitreal, 
Bevacizumab, Diabetic Retinopathy 
Introduction 
As the prevalence of diabetes is increasing in the 
world, Diabetic retinopathy (DR) is becoming a most 
important public health problem and threat to sight in 
the working-age population.1, 2 It is also a major cause 
of blindness in developing countries. According to the 
Diabetic Association of Pakistan – World Health 
Organization (DAP-WHO) survey (1994-1998), overall 
prevalence of diabetes in Pakistani population is 
11.47%.1In diabetic retinopathy there are abnormal 
retinal blood vessels which can be either due to the 
proliferation of new vessels (proliferative retinopathy) 
or due to functionally incompetent and leaky vessels. 
The vascular endothelial growth factor (VEGF) has 
been suggested as a main factor, firstly in proliferation 
of new weak vessels which can rupture causing 
vitreous hemorrhage and resulting in decrease visual 
acuity, and secondly it causes the breakdown of the 
blood-retinal barrier causing increased vascular 
permeability which results in retinal edema by 
disturbing the endothelial tight junction proteins. This 
retinal edema in macular area is called diabetic 
macular edema and when it fulfills a certain clinical 
criteria, it is known as clinically significant macular 
edema.2, 3  
Most of the adults became blind due to proliferative 
diabetic retinopathy (PDR) and principally treated by 
pars plana vitrectomy and Argon laser but the 
bleeding from fibrovascular membrane (FVM) is still a 
risk to be considered. A humanized vascular 
endothelial growth factor (VEGF) antibody known as 
Bevacizumab (Avastin Genetech Inc, South San 
Francisco, California, USA) previously used for 
metastatic colorectal carcinoma but recent reports have 
showed its effectiveness in the treatment of 
neovascular disorder in the eye like proliferative 
diabetic retinopathy and in diabetic macular edema.4  
 Though the normal human retina contains VEGF, its 
levels are considerably raised in eyes with diabetic 
macular edema(DME) and proliferative diabetic 
retinopathy( PDR). Therefore, intravitreal anti-VEGF 
treatments have been recommended as an adjunctive 
treatment for DME.3 The drug acts by decreasing the 
size and number of new vessels and also helps in 
resolving the vitreous hemorrhage . Currently, some 
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anti-VEGF drugs, including pegaptanib, ranibizumab, 
bevacizumab, and aflibercept, are available.5 
Bevacizumab (Avastin, Genentech Inc., San Francisco, 
CA) is a complete full-length humanized antibody, it 
binds to  and competitively inhibits all isoforms of the 
VEGF-A family. While bevacizumab is presently FDA 
approved for the treatment of metastatic colorectal 
cancer, metastatic breast cancer, and non-small cell 
lung cancer , it is widely used off-label for treatment of 
ocular diseases like retinal vein occlusion, neovascular 
age-related macular degeneration, DME, proliferative 
diabetic retinopathy, rubeosis irides, and retinopathy 
of prematurity5. 
Although intravitreal use of bevacizumab is an off-
label option, its use has increased exponentially in the 
past few years primarily due to its efficacy and cost 
effectiveness.5 The purpose of this study was to 
evaluate the efficacy of monthly intravitreal 
bevacizumab injections (1.25 mg/.05 ml) in improving 
or stabilizing visual outcomes (best corrected visual 
acuity (BCVA)), as measured by snellen’s visual acuity 
charts, for diabetic retinopathy. 
 
Patients and Methods  
This  prospective study which was conducted at 
Benazir Bhutto Hospital, Rawalpindi  from July to  
June 2015.A total number of 59 eyes of 59 patients 
were selected on the basis of non-probability, 
purposive sampling. Inclusion criteria was diabetic 
patients with vitreous hemorrhage (associated with 
proliferative diabetic retinopathy) with absence of 
tractional retinal detachment on B-scan 
ultrasonography,diabetic macular edema with any 
stage of  non proliferative diabetic  retinopathy  and  
diabetic macular edema with proloferative diabetic 
retinopathy but without vitreous hemorrhage. Diabetic 
patients who had received prior treatments with other 
modalities like laser photocoagulation, intravitreal 
Ranibizumab, intravitreal or posterior subtenon 
triamcinolone, patients with anterior segment diseases, 
diseases affecting the vision like corneal opacity, 
uveitis, glaucoma, visually significant cataract, etc. due 
to which exact role of bevacizumab, regarding visual 
outcome, cannot be assessed .Patients with other 
associated posterior segment diseases affecting the 
vision like age related macular degeneration, central 
retinal vein occlusion, central retinal artery occlusion, 
retinal detachment (rhegmatogenous, tractional, 
serous, all type of), opic nerve disease, etc and patients 
who developed any complications of intravitreal 
Bevacizumab which can affect the visual acuity , were  
excluded. Pre-operatively visual acuity was measured 
using snellen’s acuity chart, complete anterior segment 
and posterior segment examination was done using 
slit lamp, +90D lens, indirect ophthalmoscopy. 
Intraocular pressure (IOP) was measured using 
Goldman applanation tonometer. Fundus Fluorescein 
Angiography and B-scan ultrasound examinations 
were done where necessary. The risks and benefits of 
treatment were discussed and informed consent was 
taken .All the patients included in the study received 
intravitreal bevacizumab with a dose of 1.25mg in 
0.05ml and given by the same surgeon. Topical 
anesthetic proparacaine was given before injection and 
repeated as necessary. All the injections were given 
with strict sterile technique (cleaning conjunctival sac 
with diluted povidone iodine) under full aseptic 
conditions in operation theatre.  Injection was given 
4mm, 3.5mm, 3mm posterior to the limbus in phakic, 
psuedophakic and aphakic eyes respectively through 
the infero-temporal pars plana with a 30-gauge needle 
. The injection site was compressed for several seconds 
to avoid reflux of avastin when the needle was 
removed. Patients were advised to use antibiotic and 
steroid combination eye drops for 07 days after the 
intravitreal injection. Follow up was scheduled after 1 
week, 4 weeks and every month till the end of follow 
up at 3 months. Follow up visits included checking 
visual acuity by snellen’s chart and complete ocular 
examination. At each visit complications like 
endophthalmitis, vitreous hemorrhage (not present 
pre-injection , in case of macular edema), traumatic 
cataract, uveitis, retinal detachment which can affect 
the visual acuity, were evaluated . The primary end 
point of the treatment was a change in best corrected 
visual acuity from baseline over 03 months. The 
maximum number of injections given was three for 
each eye and they were given four weeks apart.The 
criteria for improvement was a gain of at least one line 
on snellen’s visual acuity chart , compared to the 
baseline while stabilization was considered if the 
visual acuity on the snellen’s chart was unchanged 
relative to the baseline. 
 
Results 
Out of  59 diabetic patients, 42.4% were males and 
57.6% were  females. The age range was from 45 to 67 
years with a mean of 53.02 ± 9.79. (Table 1). All 
patients completed 1 month of follow-up after the last 
injection. The glycosylated hemoglobin (HbA1c) was 
6.0 ± 1.3 at baseline. Pre-injection, there were  16 (27%) 
eyes with best corrected visual acuity (BCVA) better 
than or equal to 6/15, 27 eyes (45%) with VA between 
6/24 and 6/60 and 16 (27%) with VA below 6/60. At 
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the end of 1 month of follow up after 3rd injection, 37 
(62.7%) eyes had BCVA better than or equal to 6/15; 
18 (30.50%) between 6/24 and 6/60 and in 4 (6.7%) 
eyes the vision was worse than 6/60. Two  (10%) eyes 
had BCVA better than or equal to 6/18. So, the final 
assessment was 1 month after the 3rd injection.A total 
number of 59 patients,  25 males and 34 females with 
an age range of 40-65 years, mean age 53.02 (± SD 9.79) 
 were subjected to intravitreal injection of 
bevacizumab (Table 1 ). Out of the total 59 eyes, 30 
(50.84%) had diabetic macular edema and 29 (49.16%) 
with diabetic vitreous hemorrhage (DVH) (Table 2).  
 
Table 1: Patient’s characteristics 
Age range 40-65 
Males  25 (42.4%) 
Females 34 (57.6%) 
No. of patients 59 
Duration of study 1 year 
Average follow up 3 months 
Table 2: frequency of DME and  
vitreous hemorrhage 
Total number of eyes   59 
DME 30 (50.84%) 
Vitreous hemorrhage 29 (49.16%) 
Table 3: Baseline visual acuity (preinjection) 
Baseline visual 
acuity 
DME(No. of eyes) DVH(No. of eyes) 
6/300     10     5 
6/150      1     - 
6/60      1     - 
6/30      8      5 
6/24      7     6     
6/15      3    11 
6/12       -     2 
Twenty six  eyes (44.06%) with diabetic macular 
edema showed improvement while visual acuity was 
stabilized in 4 eyes (6.7%). In patients with diabetic 
vitreous hemorrhage associated with proliferative 
diabetic  retinopathy (PDR) with vitreous hemorrhage, 
45.76%eyes showed improvement while stabilization 
of visual acuity was noted in 2 eyes (3.3%). No patient 
with worsening of visual acuity was noted. A 
significant outcome in visual acuity was noted (Table 
3-5; Figure 1). The Wilcoxon test was used for 
comparison of preoperative and postoperative BCVA 
(Table 6). For all statistical tests a p value of <0.05 was 
considered statistically significant and in our study it 
is <0.05 which is statistically significant. Snellen visual 
acuity was converted to Log MAR for data analysis.No 
systemic side effects of the given treatment were 
observed.However amongst the local side effects, sub-
conjunctival hemorrhage was the most frequent; 
occured in 20 eyes (19.6%). Complications like 
endophthalmitis, retinal detachment or traumatic 
cataracts were not seen in any case. 
 
Table 4: Visual outcomes of IVB: Post injection 
improvement at 3 months 
Post Injection 
visual acuity 
DME(No. of eyes) DVH(No. of eyes) 
6/6 - 2 
6/7.5 3 11 
6/12 2 3 
6/15 8 8 
6/24 2 2 
6/30 3 3 
6/60 8 - 
6/300 4 - 
 
Table 5: Pre and post injection visual acuities 




no. of eyes 
Post injection, no. of 
eyes 
6/6 – 6/15 16 37 
6/24 – 6/60 27 18 


















Figure 1. Mean visual acuity before and after injection 
 
Table 6: Wilcoxon test: 









0.921 0.562 0.001 
 
Discussion 
Common causes of visual loss in patients of diabetic 
retinopathy are macular edema, vitreous haemorrhage 
and tractional retinal detachment. In patients of 
diabetic retinopathy, angiogenic mediators such as 
insulin like growth factor-1, erythropoietin, fibroblast 
growth factor and endothelial growth factor (VEGF) 
are released as a result of  retinal ischemia and lead to 
the formation of new vessels in the retina. Vitreous 
hemorrhage occurs as a result of these neovascular 
growths and by precluding the retinal view, prevents 
panretinal photocoagulation, the gold standard 
treatment in proliferative diabetic retinopathy. The 
clinical use of anti-angiogenic agents has developed 
new opportunities for the treatment of retinal vascular 
disorders. Considering the antiangiogenic therapy, it 
accelerates the resolution of hemorrhage and facilitates 
PRP. So, it’s a good choice for patients with vitreous 
hemorrhage.6 
Diabetic macular edema is the main cause of 
decreased central vision in patients with diabetic 
retinopathy. It can be diffuse or localized. Clinically 
significant macular edema includes  retinal thickening 
within 500 µm of the center of the fovea, hard exudates 
within 500 µm of the center with associated retinal 
thickening (which may be outside the 500 µm) and at 
least one disc diameter of retinal thickening, any part 
of which is within one disc diameter of the center of 
the fovea. 7 Diagnosis of macular edema is clinical but 
we also confirmed our diagnosis by fundus fluorescein 
angiography, the available investigation in our 
department. Anti-angiogenic agents have been proved 
to be effective in resolving this macular edema. The 
agent which we used was Bevacizumab. 
 Bevacizumab was first approved by the US Food and 
Drug Administration (FDA), for the treatment of 
carcinomas8. Bevacizumab is used as an off-label 
treatment intravitrealy for ocular diseases with high 
levels of VEGF, such as choroidal neovascularization 
(CNV), proliferative diabetic retinopathy, diabetic 
maculopathy and retinal vein occlusion.8 
VEGF, was first documented in 1989 by Napoleon 
Ferrara.8VEGF inhibition induces several effects on 
endothelial cells including inhibition of proliferation.8 
Bevacizumab has been used on “off-label” basis since 
2005. It is used as first line treatment in macular 
degeneration because of its cost effectiveness as 
compared to other drugs like Lucentis and Macugen 
(FDA approved antiVEGF).9,10 The most common 
indications of Bevacizumab shown in one paper by 
Lihteh Wu et al  were diabetic retinopathy and CNV of 
several etiologies.11 Similarly in our study, the main 
indications were diabetic retinopathy, with diabetic 
macular edema (50.84%) and PDR  with vitreous 
hemorrhage(49.1%). 
In diseases like diabetic retinopathy, diabetic 
maculopathy, and retinal vein occlusions, increased 
levels of VEGF were found in vitreous. Regardless of a 
large antibody, bevacizumab confirmed full 
penetration of retina12. No evidence of a noxious effect 
was observed in patients treated with 1.25mg of  
bevacizumab measured by full field and multifocal 
ERG.13 
In a prospective study of patients with proliferative 
diabetic retinopathy treated with intravitreal injections 
of  bevacizumab, a rapid regression of actively leaking 
neovascularization, as well as significant improvement 
in mean visual acuity from 20/160 to 20/125 at three 
months follow up, was found.14 In our prospective 
study, out of 59 patients with diabetic macular edema 
and PDR, 53 patients showed significant improvement 
(89.8%), however, 6 patients (10.2%), shows no change 
in BCVA , and there was no patient with worsening of 
visual acuity. It is comparable to a local study by 
Jahangir T, et al which also showed significant 
improvement in visual acuity in patients with diabetic 
macular edema after intravitreal Avastin.15 
In a study by Tareen IFH, the mean BCVA at base line 
was 0.42±0.14 Log Mar units. 16 This improved to 
0.34±0.13, 0.25±0.12, 0.17±0.12 and 0.16±0.14 Log Mar 
units at 1 month after 1st, 2nd 3rd injections and at final 
visit at 6 months respectively, a difference that was 
statistically significant (P>0.0001) from base line. The 
mean 1mm central macular thickness measurement 
was 452.9 ± 143.1 µm at base line, improving to 279.8 ± 
65.2 µm (P<0.0001) on final visit.In a study of Bahoo 
MLA , Overall improvement rate was 11 (15.7%) with 
signifcant improvement from 1.028 log MAR at 
baseline to 0.99 at 12 weeks. 17In a study of Bokhari 
SA,mean central macular thickness (CMT) reduced 
from 502µm to 384µm. 18In a study of Shaikh FF, mean 
central macular thickness was 520.40±139.1 µm at 
baseline, which decreased to 385.90±98.30 µm 
(p<0.0001) at one month and to 427.40±112.6 µm 
(p=<0.0001) at three months.19 
Conclusion 
1.Anti-VEGF therapy is the mainstay for the treatment 
of many retinal diseases.  
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2.Treatment with Bevacizumab is beneficial in 
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